Reckitt Benckiser announces early termination of antitrust waiting period for Adams purchase

SLOUGH, U.K. Reckitt Benckiser’s bid for the business Adams Respiratory Therapeutics won’t run into any legal hurdles—the company announced Tuesday that they have received early termination of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 relating to the previously-announced tender offer to purchase all of the outstanding shares of common stock of Adams.

Reckitt Benckiser initiated, through its wholly owned subsidiary Twickenham, a cash tender offer on Dec. 21 to purchase all outstanding shares of common stock of Adams for $60 per share.

That tender offer expires at midnight in New York on Jan. 23, however.